Uzbekistan Ўзбекча
Uzbekistan Ўзбекча Uzbekistan Ўзбекча Global English Poland polski Czechia Český Italy Italiano Kazakhstan Қазақ Slovakia Slovenský Spain Español Russia Pусский Ukraine Український Vietnam Tiếng việt

Patentlangan dori vositalarini ishlab chiqish

Biz onkologik va neyropsixiatrik yangi dori vositalarini izlaymiz

Adamedda patentlangan dori vositalarini ishlab chiqish ikkita davolash sohalarida jamlangan: onkologiya va neyropsixiatriya. Biz multifunksional ekspertlar jamoamiz va jamoa ihtiyoridagi zamonaviy texnologik muassasalar sharofati bilan yangi molekulalarni ishlab chiqish kabi juda murakkab loyihalarni amalga oshirish imkoniyatiga egamiz.
 

Laboratoriyalarimiz potensial dori preparatlarini tanlash va sinash hamda klinik ishlanma darajasiga oʻtkazish maqsadida texnologiyalarning moslashuvchan kombinatsiyasini taqdim etadi. Biz kimyoviy birikmalar va biologik molekulalar, bioximiya va biofizika, hujayra biologiyasi, toʻqimalar biologiyasi, farmakokinetika, toksikologiya va psixologiyaga oid sintez va analitik maʼlumotlar boʻyicha zarur nou-xaularga egamiz. Tadqiqot loyihalarimizda zamonaviy matematik, analitik va in silico modellashtirish vositalaridan foydalanamiz.

Hozirda uchta potensial dori preparatlari molekulalari boʻyicha toʻrtta yirik tadqiqot dasturi doirasida bir nechta loyihalarni olib bormoqdamiz. Ulardan birinchisi – sarkoma, limfoma va leykozda saratonga qarshi kurash faoliyatini aks ettiruvchi MDM2 ajratuvchi ingibitor. Ikkinchisi – ikki tomonlama taʼsir kuchiga ega 5-HT6 va 5-HT2A serotonin retseptorlariga yoʻnaltirilgan ligand. Kelgusida bu molekula aqliy zaif bemorlardagi psixik va kognitiv xastaliklarni davolashda qoʻllanilishi kutilmoqda. Uchinchi molekula – bu pro-apoptotik va antiangiogen taʼsirli rekombinant birikuvchi oqsil. Bu oshqozon-ichak yoʻlidagi zich oʻsimtalarga qarshi potensial dori preparatidir.

Pipeline

Discovery Lead optimisation Tox Phase I

Oncology

AD-O51.4

Phase:

AD-O21.32

Phase:

BIOCON

Phase:

Neuropsychiatry

PIRDINENSERIN

Phase:
is an anticancer fusion protein with dual activity: proapoptotic – triggering cell death through DR4/DR5 selectively on cancer cells and antiangiogenic – through interactions with VEGF receptor. It is a homotrimer of recombinant variant of human TRAIL linked to the VEGF-derived short sequence. AD-O51.4 protein exhibits superior in vivo efficacy in a number of xenograft models, including PDX (e.g. liver, pancreas, esophagus, colon, uterus sarcoma) and good safety profile. Currently, tox batch manufacturing is ongoing.
lead compound and its derivatives are anticancer small-molecules that act through inhibition of MDM2-p53 interaction, reactivate p53 protein and induce apoptosis of cancer cells. AD-O21 are more effective than the major competitors in in vitro assays and in in vivo xenograft model. They have high bioavailability and cause total tumor regression after oral administration in sensitive cancer models. The preliminary toxicity studies confirm the safety of AD-O21. Currently, tox batch manufacturing is ongoing.
The BIOCON program aims to develop molecules with anticancer activity which would selectively target neoplastically transformed tissue while remaining safe for the healthy cells. The idea behind this project is to use molecules in the form of bioconjugates. The first molecule element – a protein carrier, derived from in silico modeling, phage display screening and animal immunization – is responsible for targeting tumor cells and then interacting with their surface. Additionally it aims to block the pro-survival signaling or induce cell death pathway. The other molecule element is a chemical compound with potent cytotoxic effects which, guided by the carrier, will be released primarily at a desired location.
is a novel program targeting dementia-related psychosis, e.g. the Alzheimer’s Disease psychosis (ADP). Lead molecules from the PIRDINENSERIN program offer: potent antipsychotic-like activity in hyperserotonergic models in adult and OLD rats and potent pro-cognitive activity in hypocholinergic model in rat (p.o.); central target engagement proof-of-concept in rat (dose dependent); selective, dual blockade of 5-HT6 and 5-HT2 receptors – novel mechanism of action; no activities associated with side-effects: anticholinergic properties, hERG blockade etc. Two lead candidates selected for formal preclinical development. Currently, tox batch manufacturing is ongoing.

Hamkorlarimiz

Hamkorlarimiz

Varshavadagi Polsha Fanlar akademiyasi Bioximiya va biofizika instituti

Varshavadagi Polsha Fanlar akademiyasi Fizikaviy kimyo instituti

Vrotslavdagi Polsha Fanlar akademiyasi Immunologiya va eksperimental terapiya instituti

EiT+ Vrotslav tadqiqot markazi

Jagiellonian universiteti Bioximiya, biofizika va biotexnologiya fakulteti

Xalqaro Molekulyar va hujayra biologiyasi instituti

Xalqaro Molekulyar va hujayra biologiyasi instituti

Farmasevtika tadqiqot instituti

Jagiellonian universiteti Tibbiyot kollejining Farmatsevtika fakulteti

Lublindagi John Paul II Katolik universiteti

Krakovdagi Polsha Fanlar akademiyasi Farmakologiya instituti

Psixiatriya va neurologiya instituti

Ona va bola instituti

Gematologiya va transbirikuvchi dori vositalari instituti

Maria Skłodowska-Curie instituti Onkologiya markazi

Malaka oshirish Tibbiyot markazi